Persistence, Clinical and Economic Impact of Infliximab CT-P13 in Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Naïve and Switched Patients: After 5 Years of Follow-Up
Bibliographic record
Abstract
Objective: Study the economic impact and persistence of Inflectra® in rheumatoid arthritis (RA), psoriatic arthropathy (PSA), psoriasis, ankylosing spondylitis (AS) naïve, and Remicade® switched patients. Methods: Retrospective observational cohort study of patients treated with Inflectra® for more than six months in a five years analysis. We collected age, sex, indication, dose, and persistence (in years) for Inflectra® naïve and Remicade® switched patients. Efficacy endpoints included a disease activity score calculator for rheumatoid arthritis (DAS28) and bath ankylosing spondylitis disease activity index (BASDAI). Safety was also assessed. We determined each patient's actual cost of Inflectra® treatment from individualized IV administration and correlated dates during the study period. We simulated the actual cost of these patients if the patients received Remicade®. Results: During five years, 62 patients (38 women; 31 AS, 18 RA, 13 PSA were treated with Inflectra®. 33 (53%) patients were naïve patients, and 29 (47%) were Remicade® switched patients. In Sept 2019, 33 patients continued on Inflectra® treatment (11 naïve; 22 Remicade® switched) in clinical remission. Twenty-nine patients discontinued therapy, 24 due to relapse, and five due to adverse reactions. All patients with Inflectra® presented a persistence of 24.4±7.4 months. The persistence in naïve patients was 19.1±4.4 months and in Remicade® switched patients was 29.7±5.8 months. The total associated costs of the Inflectra® treatment throughout the observation period were 901.840€. If these patients had been treated with Remicade®, the total cost of therapy would have been 1.099.803€. The use of Inflectra® saved 197,964€ during five years. Conclusions: Inflectra® produces similar persistence and substantial cost savings when used in Infliximab naïve patients and Remicade® switched patients.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".